Compare PCT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | IMNM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | PCT | IMNM |
|---|---|---|
| Price | $10.57 | $20.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.67 | ★ $31.44 |
| AVG Volume (30 Days) | ★ 4.2M | 3.5M |
| Earning Date | 02-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,660,000.00 | ★ $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $723.85 | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.40 | $5.15 |
| 52 Week High | $17.37 | $25.30 |
| Indicator | PCT | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 51.08 |
| Support Level | $9.88 | $19.60 |
| Resistance Level | $10.75 | $22.01 |
| Average True Range (ATR) | 0.51 | 1.09 |
| MACD | 0.22 | -0.22 |
| Stochastic Oscillator | 93.78 | 38.16 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.